ArticleHepatology international2026
Trends in MASLD-related cirrhosis and liver cancer across diverse populations, 2010-2023.
Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
BACKGROUND/
aimsMetabolic dysfunction-associated steatotic liver disease (MASLD) is now a leading cause of liver complications. This study aims to evaluate the temporal trends in the burden of MASLD-related cirrhosis and liver cancer from 2010 to 2023.
methodsUsing data from the Global Burden of Disease Study 2023, we analyzed trends in cirrhosis and liver cancer attributed to MASLD across eight selected countries. Incidence, prevalence, and mortality were analyzed and stratified by gender and age.
resultsIn 2023, China reported the highest number of MASLD-related chronic liver diseases (CLD) including cirrhosis cases, with approximately 288.64 million cases, and the highest number of liver cancer cases, at 13,780. The US recorded the highest mortality for MASLD-related CLD including cirrhosis with 6,241 deaths, while China had the highest liver cancer mortality at 9,260 deaths. From 2010-2023, trends showed significant heterogeneity. South Africa experienced the largest increase in cirrhosis prevalence (+ 52.7%), whereas South Korea was the only country with a declining incidence rate (-8.3%). The UK exhibited the most significant increase in MASLD-related liver cancer, with a 100.22% increase in prevalence and a 96.31% rise in new cases. Japan was the only country to show a decline in liver cancer burden. Generally, males bore a higher burden of MASLD-related cirrhosis and liver cancer than females, though notable exceptions existed in specific regions.
conclusionsThe burden of MASLD-related CLD including cirrhosis and liver cancer represents a significant and growing global public health challenge. Based on current trends, recommendations should prioritize improved risk stratification, early detection of advanced liver disease, and prevention targeting metabolic risk factors.
Indexed as
Identifiers
42350875What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.